CN111187220B - 含席夫碱结构单元的三氟甲基嘧啶类衍生物及其制备方法和用途 - Google Patents
含席夫碱结构单元的三氟甲基嘧啶类衍生物及其制备方法和用途 Download PDFInfo
- Publication number
- CN111187220B CN111187220B CN202010057671.7A CN202010057671A CN111187220B CN 111187220 B CN111187220 B CN 111187220B CN 202010057671 A CN202010057671 A CN 202010057671A CN 111187220 B CN111187220 B CN 111187220B
- Authority
- CN
- China
- Prior art keywords
- trifluoromethyl
- pyrimidine
- prop
- hydrazino
- ylthio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 239000002262 Schiff base Substances 0.000 title claims abstract description 16
- 150000004753 Schiff bases Chemical class 0.000 title claims abstract description 16
- BQDJLAWUTBCDHK-UHFFFAOYSA-N 2-(trifluoromethyl)pyrimidine Chemical class FC(F)(F)C1=NC=CC=N1 BQDJLAWUTBCDHK-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 7
- PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 claims description 24
- -1 3, 4-difluorophenyl Chemical group 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 11
- 239000001431 2-methylbenzaldehyde Substances 0.000 claims description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 claims description 8
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 claims description 8
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 claims description 7
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- XXFUZSHTIOFGNV-UHFFFAOYSA-N 1-bromoprop-1-yne Chemical compound CC#CBr XXFUZSHTIOFGNV-UHFFFAOYSA-N 0.000 claims description 4
- FPYUJUBAXZAQNL-UHFFFAOYSA-N 2-chlorobenzaldehyde Chemical compound ClC1=CC=CC=C1C=O FPYUJUBAXZAQNL-UHFFFAOYSA-N 0.000 claims description 4
- JPHKMYXKNKLNDF-UHFFFAOYSA-N 3,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1F JPHKMYXKNKLNDF-UHFFFAOYSA-N 0.000 claims description 4
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 claims description 4
- IAVREABSGIHHMO-UHFFFAOYSA-N 3-hydroxybenzaldehyde Chemical compound OC1=CC=CC(C=O)=C1 IAVREABSGIHHMO-UHFFFAOYSA-N 0.000 claims description 4
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 claims description 4
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- QPHZAQKLSMXZLE-AWQFTUOYSA-N N-[(E)-(3-fluorophenyl)methylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CC(=CC=C2)F)C(F)(F)F QPHZAQKLSMXZLE-AWQFTUOYSA-N 0.000 claims description 4
- ZDNYZHIOJDALOJ-AWQFTUOYSA-N N-[(E)-(4-fluorophenyl)methylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CC=C(C=C2)F)C(F)(F)F ZDNYZHIOJDALOJ-AWQFTUOYSA-N 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- YMNKUHIVVMFOFO-UHFFFAOYSA-N anthracene-9-carbaldehyde Chemical compound C1=CC=C2C(C=O)=C(C=CC=C3)C3=CC2=C1 YMNKUHIVVMFOFO-UHFFFAOYSA-N 0.000 claims description 4
- CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 3
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 claims description 3
- ISDBWOPVZKNQDW-UHFFFAOYSA-N 4-phenylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CC=CC=C1 ISDBWOPVZKNQDW-UHFFFAOYSA-N 0.000 claims description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 3
- OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 claims description 3
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 claims description 3
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 claims description 3
- KTMNPWCZNGBVNO-DJKKODMXSA-N 2-prop-2-ynylsulfanyl-N-[(E)-pyridin-2-ylmethylideneamino]-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CC=CC=N2)C(F)(F)F KTMNPWCZNGBVNO-DJKKODMXSA-N 0.000 claims description 2
- JWGQPPIGVDQKBJ-DJKKODMXSA-N 2-prop-2-ynylsulfanyl-N-[(E)-pyridin-3-ylmethylideneamino]-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CN=CC=C2)C(F)(F)F JWGQPPIGVDQKBJ-DJKKODMXSA-N 0.000 claims description 2
- JKLQGBHBGWKLDN-DJKKODMXSA-N 2-prop-2-ynylsulfanyl-N-[(E)-pyridin-4-ylmethylideneamino]-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CC=NC=C2)C(F)(F)F JKLQGBHBGWKLDN-DJKKODMXSA-N 0.000 claims description 2
- JNXKGRJQGPOPKA-DJKKODMXSA-N 3-[(E)-[[2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-yl]hydrazinylidene]methyl]phenol Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CC(=CC=C2)O)C(F)(F)F JNXKGRJQGPOPKA-DJKKODMXSA-N 0.000 claims description 2
- YGPHOVHTKMEVRY-AWQFTUOYSA-N N-[(E)-(2-chlorophenyl)methylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CC=CC=C2Cl)C(F)(F)F YGPHOVHTKMEVRY-AWQFTUOYSA-N 0.000 claims description 2
- NUKIWCLHCLEMGT-KEBDBYFISA-N N-[(E)-(2-methylphenyl)methylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound CC1=CC=CC=C1/C=N/NC2=NC(=NC(=C2)C(F)(F)F)SCC#C NUKIWCLHCLEMGT-KEBDBYFISA-N 0.000 claims description 2
- UBQJZCGPNRQTMC-ODCIPOBUSA-N N-[(E)-(3,4-difluorophenyl)methylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CC(=C(C=C2)F)F)C(F)(F)F UBQJZCGPNRQTMC-ODCIPOBUSA-N 0.000 claims description 2
- HQQMTEMKGPHHCE-AWQFTUOYSA-N N-[(E)-(3-chlorophenyl)methylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CC(=CC=C2)Cl)C(F)(F)F HQQMTEMKGPHHCE-AWQFTUOYSA-N 0.000 claims description 2
- GHDOPKDRWOVZNF-AWQFTUOYSA-N N-[(E)-(4-chlorophenyl)methylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CC=C(C=C2)Cl)C(F)(F)F GHDOPKDRWOVZNF-AWQFTUOYSA-N 0.000 claims description 2
- YLSYSMZPKLCUAF-KEBDBYFISA-N N-[(E)-(4-methylphenyl)methylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound CC1=CC=C(C=C1)/C=N/NC2=NC(=NC(=C2)C(F)(F)F)SCC#C YLSYSMZPKLCUAF-KEBDBYFISA-N 0.000 claims description 2
- GFKHAWLXCLNRGX-AFUMVMLFSA-N N-[(E)-(4-phenylphenyl)methylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=CC=C(C=C2)C3=CC=CC=C3)C(F)(F)F GFKHAWLXCLNRGX-AFUMVMLFSA-N 0.000 claims description 2
- BUYUXVBVESAVBH-MZJWZYIUSA-N N-[(E)-anthracen-9-ylmethylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=C3C=CC=CC3=CC4=CC=CC=C42)C(F)(F)F BUYUXVBVESAVBH-MZJWZYIUSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 229940125782 compound 2 Drugs 0.000 claims 2
- 229940126214 compound 3 Drugs 0.000 claims 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 4
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002147 killing effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 46
- 239000007787 solid Substances 0.000 description 29
- 238000004896 high resolution mass spectrometry Methods 0.000 description 25
- 239000000843 powder Substances 0.000 description 21
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- PKZJLOCLABXVMC-UHFFFAOYSA-N 2-Methoxybenzaldehyde Chemical group COC1=CC=CC=C1C=O PKZJLOCLABXVMC-UHFFFAOYSA-N 0.000 description 6
- WMPDAIZRQDCGFH-UHFFFAOYSA-N 3-methoxybenzaldehyde Chemical group COC1=CC=CC(C=O)=C1 WMPDAIZRQDCGFH-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- JIVGSHFYXPRRSZ-UHFFFAOYSA-N 2,3-dimethoxybenzaldehyde Chemical group COC1=CC=CC(C=O)=C1OC JIVGSHFYXPRRSZ-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 239000012295 chemical reaction liquid Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 150000003230 pyrimidines Chemical class 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 4
- FIZSTSIFYANHAU-UHFFFAOYSA-N 2-(1h-indol-3-yl)benzaldehyde Chemical group O=CC1=CC=CC=C1C1=CNC2=CC=CC=C12 FIZSTSIFYANHAU-UHFFFAOYSA-N 0.000 description 3
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- OESBXOZMKADVKB-UHFFFAOYSA-N 3-prop-2-ynylsulfanyl-5-(trifluoromethyl)phenol Chemical compound C#CCSC1=CC(=CC(=C1)O)C(F)(F)F OESBXOZMKADVKB-UHFFFAOYSA-N 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- OVWYEQOVUDKZNU-UHFFFAOYSA-N m-tolualdehyde Chemical group CC1=CC=CC(C=O)=C1 OVWYEQOVUDKZNU-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTXQJYXDBMATLL-UHFFFAOYSA-N 1-chloro-3-prop-2-ynylsulfanyl-5-(trifluoromethyl)benzene Chemical compound C#CCSC1=CC(=CC(=C1)C(F)(F)F)Cl MTXQJYXDBMATLL-UHFFFAOYSA-N 0.000 description 1
- FXPVWFBGUQUFEE-UHFFFAOYSA-N 2-pyridin-2-ylbenzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=CC=N1 FXPVWFBGUQUFEE-UHFFFAOYSA-N 0.000 description 1
- DTUANRRVVJRTJS-UHFFFAOYSA-N 2-pyridin-3-ylbenzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=CN=C1 DTUANRRVVJRTJS-UHFFFAOYSA-N 0.000 description 1
- HPSCYFZOYJSYGZ-UHFFFAOYSA-N 2-pyridin-4-ylbenzaldehyde Chemical compound O=CC1=CC=CC=C1C1=CC=NC=C1 HPSCYFZOYJSYGZ-UHFFFAOYSA-N 0.000 description 1
- ZRSNZINYAWTAHE-PTQBSOBMSA-N 4-methoxybenzaldehyde Chemical group COC1=CC=C([13CH]=O)C=C1 ZRSNZINYAWTAHE-PTQBSOBMSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- MDHNWHIVJQUVHY-ZVBGSRNCSA-N N-[(E)-2-benzothiophen-1-ylmethylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=C3C=CC=CC3=CS2)C(F)(F)F MDHNWHIVJQUVHY-ZVBGSRNCSA-N 0.000 description 1
- OEHVWLUWBYQIDD-LSHDLFTRSA-N N-[(E)-2H-isoindol-1-ylmethylideneamino]-2-prop-2-ynylsulfanyl-6-(trifluoromethyl)pyrimidin-4-amine Chemical compound C#CCSC1=NC(=CC(=N1)N/N=C/C2=C3C=CC=CC3=CN2)C(F)(F)F OEHVWLUWBYQIDD-LSHDLFTRSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- HUMNYLRZRPPJDN-KWCOIAHCSA-N benzaldehyde Chemical group O=[11CH]C1=CC=CC=C1 HUMNYLRZRPPJDN-KWCOIAHCSA-N 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于药物化学领域，公开了具有抗肿瘤活性的含席夫碱结构单元的三氟甲基嘧啶类衍生物及其制备方法和用途。本发明化合物具有通式Ⅰ结构。体外抗肿瘤活性评价发现该系列化合物对多种肿瘤细胞具有明显的抑制和杀伤作用。可以将其应用于制备临床预防、治疗癌症药物。
Description
技术领域
本发明属于药物化学领域，涉及嘧啶类衍生物，具体涉及抗肿瘤活性的基于含席夫碱结构单元的三氟甲基嘧啶类衍生物及其制备方法和用途。
背景技术
肿瘤是当今世界危及人类生命健康的最常见、最严重的疾病之一。目前已上市的抗肿瘤药物有很多，嘧啶类化合物表现出了广泛的生物活性，例如：抗癌、抗菌、抗炎和抗惊厥等。其抗肿瘤活性的优秀代表为：厄洛替尼(Erlotinib)、拉帕替尼(Lapatinib)等。但已开发的药物远不能满足患者的需求，因此，研究与开发具有高效、低毒的抗肿瘤药物具有深远的意义。席夫碱具有抑菌、杀菌、抗肿瘤、抗病毒的生物活性等特殊的生理活性，近年来，越来越引起医药界的重视。三氟甲基可增强化合物的生物活性、亲油性、代谢稳定性和选择性，将其引入到嘧啶类化合物，有可能有效地改变嘧啶类化合物的极性、亲脂性、代谢稳定性。因此，在嘧啶的四位，引入三氟甲基，以其作为基本母核，再对其进行结构修饰，引入席夫碱合成基于含席夫碱结构单元的三氟甲基嘧啶类衍生物，对其进行活性研究具有非常重要的研究价值，有利于我国自主产权药物的开发。
发明内容
为开发利用现有的临床药物资源，本发明目的在于提供一类基于含席夫碱结构单元的三氟甲基取代的嘧啶类衍生物，为寻找新的抗肿瘤活性化合物开辟一条新途径；本发明另一目的在于提供其在制备抗肿瘤药物中的应用。
本发明所述基于三氟甲基取代的嘧啶类衍生物的结构通式如下：
通式Ⅰ中：R为苯甲醛基、3-氟苯甲醛基、4-氟苯甲醛基、2-氯苯甲醛基、3-氯苯甲醛基、4-氯苯甲醛基、3,4-二氟苯甲醛基、2-甲基苯甲醛基、3-甲基苯甲醛基、4-甲基苯甲醛基、2-甲氧基苯甲醛基、3-甲氧基苯甲醛基、4-甲氧基苯甲醛基、2,3-二甲氧基苯甲醛基、2-噻吩苯甲醛基、3-吲哚苯甲醛基、2-吡啶苯甲醛基、3-吡啶苯甲醛基、4-吡啶苯甲醛基、9-蒽醛基、4-苯基苯甲醛基、4-羟基苯甲醛基、3-羟基苯甲醛基、3-吲哚甲醛基。
优选以下化合物：
5a:(E)-4-(2-苯基烯二肼)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5b:(E)-4-(2-(3-氟苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5c:(E)-4-(2-(4-氟苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5d:(E)-4-(2-(2-氯苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5e:(E)-4-(2-(3-氯苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5f:(E)-4-(2-(4-氯苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5g:(E)-4-(2-(3,4-二氟苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5h:(E)-4-(2-(2-甲基亚苄基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5i:(E)-4-(2-(4-甲基亚苄基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5n:(E)-4-(2-(苯并[c]噻吩-1-基亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5o:(E)-2-(丙-2-炔-1-基硫基)-4-(2-(吡啶-2-基亚甲基)肼基)-6-(三氟甲基)嘧啶；
5p:(E)-2-(丙-2-炔-1-基硫基)-4-(2-(吡啶-3-基亚甲基)肼基)-6-(三氟甲基)嘧啶；
5q:(E)-2-(丙-2-炔-1-基硫基)-4-(2-(吡啶-4-基亚甲基)肼基)-6-(三氟甲基)嘧啶；
5s:(E)-4-(2-(蒽-9-基亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5w:(E)-4-(2-([1,1'-联苯]-4-基亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5t:(E)-3-((2-(2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶-4-基)亚肼基)甲基)苯酚；
5v:(E)-1-((2-(2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶-4-基)亚肼基)甲基)-2H-异吲哚。
本发明所述基于三氟甲基取代的嘧啶类衍生物的制备方法包含以下合成步骤：a.将2-巯基-6-(三氟甲基)嘧啶-4-醇和溴代丙炔、氢氧化钾水溶液加入反应器中发生取代反应，生成4位为羟基的溴丙炔的嘧啶类生物2；b.4位为羟基的溴丙炔的嘧啶类生物2与三氯氧磷反应，生成4位为氯原子的含溴丙炔的嘧啶类生物3；c.4位为氯原子的含溴丙炔的嘧啶类生物3与水合肼在无水乙醇中反应生成化合物4；d.化合物4与不同的醛反应得到目标化合物5a-5y。
合成路线如下：
所述的醛类化合物为：苯甲醛、3-氟苯甲醛、4-氟苯甲醛、2-氯苯甲醛、3-氯苯甲醛、4-氯苯甲醛、3,4-二氟苯甲醛、2-甲基苯甲醛、3-甲基苯甲醛、4-甲基苯甲醛、2-甲氧基苯甲醛、3-甲氧基苯甲醛、4-甲氧基苯甲醛、2,3-二甲氧基苯甲醛、2-噻吩苯甲醛、3-吲哚苯甲醛、2-吡啶苯甲醛、3-吡啶苯甲醛、4-吡啶苯甲醛、9-蒽醛、4-苯基苯甲醛、4-羟基苯甲醛、3-羟基苯甲醛、3-吲哚甲醛。经体外抗肿瘤活性测试，本发明所述含席夫碱结构单元的基于三氟甲基取代的嘧啶类衍生物对人乳腺癌细胞(MCF-7)、人胃癌细胞(MGC-803)、人前列腺癌细胞(PC-3)有很好的抑制作用。其中有些化合物对乳腺癌细胞(MCF-7)、胃癌细胞(MGC-803)、前列腺癌细胞(PC-3)的IC50值小于10(μmol/L)，与临床上已使用的抗肿瘤药物5-氟尿嘧啶做对照，优于其活性。因此，本发明提供的此类含席夫碱结构单元的基于三氟甲基取代的嘧啶类衍生物为开发新型抗肿瘤药物和药物的联合用药开辟了新途径。
具体实施方式
下面结合具体实施例，进一步阐述本发明。这些实施例仅用于说明本发明而不用于限制本发明要求保护的范围。
合成化合物表征使用的仪器：NMR谱使用瑞典Bruker DPX-400型超导核磁共振仪测定，TMS为内标；高分辨质谱使用Waters-Micromass公司Q-Tof质谱仪测定。
实施例1(E)-4-(2-苯基烯二肼)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶的制备(5a)
室温条件下，将2-巯基-6-(三氟甲基)嘧啶-4-醇(1.95g,10mmol)溶于氢氧化钾(0.67g,12.05mmol)的N,N-二甲基甲酰(20ml)胺溶液中，缓慢滴入溴丙炔(940ul,12.05mmol)，升温至80℃发生取代反应，TLC检测反应完成，将反应液冷至室温，加入冰水混合物中搅拌，有大量淡黄色固体析出，抽滤，水洗3-4次，干燥，得到化合物3-(丙-2-炔-1-基硫基)-5-(三氟甲基)苯酚。
淡黄色固体，收率83.5％；1H NMR(400MHz,DMSO-d6)δ7.29(s,1H),5.19(d,J＝2.3Hz,2H),4.82(d,J＝2.3Hz,1H).13C NMR(101MHz,DMSO-d6)δ170.89,168.65,163.40,159.39,155.72,155.37,155.02,154.66,73.40,55.37,20.59,19.17.HR-MS(ESI):Calcdfor C10H8F3OS[M+H]+：233.0248,found:233.0247.
0℃条件下，将10ml三氯氧磷缓慢滴加到上述合成的3-(丙-2-炔-1-基硫基)-5-(三氟甲基)苯酚(1.15g，5mmol)中，缓慢梯度升温至90℃，继续反应3h，然后停止反应，将反应液冷至室温，逐滴加入到碎冰中，边滴加边搅拌，析出棕色固体，抽滤，水洗至中性，室温干燥，得到棕色固体(3-氯-5-(三氟甲基)苯基)(丙-2-炔-1-基)硫烷。
棕色固体，收率74.2％；1H NMR(400MHz,DMSO-d6)δ7.22(s,1H),5.20(d,J＝2.4Hz,2H),3.62–3.58(m,1H).13C NMR(101MHz,DMSO-d6)δ171.70,167.89,164.06,159.39,155.72,155.37,155.02,154.66,77.30,55.53,34.27,20.83.HR-MS(ESI):Calcd forC10H7ClF3S[M+H]+：250.9909,found:250.9908.
室温条件下，将(3-氯-5-(三氟甲基)苯基)(丙-2-炔-1-基)硫烷(2.11g，8.42mmol)加入20ml无水乙醇中，升温至80℃，缓慢加入水合肼(821ul,16.84mmol)，TLC检测反应完成，将反应液冷至室温，抽滤，得到白色固体(3-(丙-2-炔-1-基硫基)-5-(三氟甲基)苯基)肼。
白色固体,81.7％；1H NMR(400MHz,DMSO-d6)δ9.30(s,1H),6.93(s,1H),4.68(s,2H),3.94(dd,J＝24.2,8.6Hz,2H),3.12(s,1H).13C NMR(101MHz,DMSO-d6)δ170.89,168.65,163.40,159.39,155.72,155.46,154.89,154.74,149.04,74.21,73.21,55.37,33.52.HR-MS(ESI):Calcd for C10H10F3N2S[M+H]+：247.0517,found:247.0518.
室温条件下，将(3-(丙-2-炔-1-基硫基)-5-(三氟甲基)苯基)(0.15g,0.609mmol)肼加入6ml无水乙醇中，升温至80℃，缓慢加入苯甲醛(70.44ul,0.609mmol)，TLC检测反应完成，将反应液冷至室温，进行柱层析(V石油醚：V乙酸乙酯＝6：1)，浓缩洗脱剂得产物(E)-4-(2-苯基烯二肼)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶。
白色固体粉末，收率52.5％；1H NMR(400MHz,DMSO-d6)δ12.19(s,1H),8.23(s,1H),7.97(d,J＝7.3Hz,1H),7.80–7.74(m,2H),7.46(d,J＝6.4Hz,2H),7.27(s,1H),4.00(d,J＝2.4Hz,2H),3.19(t,J＝2.4Hz,1H).13C NMR(101MHz,DMSO-d6)δ192.55,169.80,161.88,145.30,141.43,139.13,132.63,130.27,128.86,127.53,126.89,126.50,119.28,95.80,79.76,73.31,18.44.HR-MS(ESI):Calcd forC15H12F3N4S[M+H]+：337.0735,found:337.0734.
实施例2(E)-4-(2-(3-氟苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶的制备(5b)
室温条件下，将(3-(丙-2-炔-1-基硫基)-5-(三氟甲基)苯基)(0.15g,0.609mmol)肼加入6ml无水乙醇中，升温至80℃，缓慢加入3-氟苯甲醛(60.97ul,0.609mmol)，TLC检测反应完成，将反应液冷至室温，进行柱层析(V石油醚：V乙酸乙酯＝6：1)，浓缩洗脱剂得产物。
白色固体，收率74.0％；1H NMR(400MHz,DMSO-d6)δ1H NMR(400MHz,DMSO)δ12.26(s,1H),8.21(s,1H),7.67(d,J＝9.8Hz,1H),7.59(d,J＝7.8Hz,1H),7.49(dt,J＝13.8,6.9Hz,1H),7.34(s,1H),7.30–7.23(m,1H),3.99(d,J＝2.6Hz,2H),3.18(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ169.92,163.66,162.15,161.23,144.41,136.43,130.88,130.79,123.59,116.89,116.68,113.10,112.88,96.17,79.88,73.44,18.57.HR-MS(ESI):Calcd for C15H11F4N4S[M+H]+：355.0641,found:355.0640.
实施例3(E)-4-(2-(4-氟苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶的制备(5c)
用4-氟苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率62.4％；1H NMR(400MHz,DMSO-d6)δ12.19(s,1H),8.22(s,1H),8.05–8.00(m,4H),7.33(s,1H),4.00(d,J＝2.5Hz,2H),3.19(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ170.09,161.97,152.63,147.84,141.66,127.28,124.40,122.01,119.16,117.08,114.31,95.70,79.91,73.40,61.18,55.75,18.57.HR-MS(ESI):Calcd forC15H11F4N4S[M+H]+：355.0641,found:355.0642.
实施例4(E)-4-(2-(2-氯苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5d)
用2-氯苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率62.7％；1H NMR(400MHz,DMSO-d6)δ12.33(s,1H),8.62(s,1H),8.13–8.05(m,1H),7.52–7.46(m,1H),7.46–7.39(m,2H),7.27(s,1H),4.00(d,J＝2.5Hz,2H),3.19(t,J＝2.5Hz,1H).13C NMR(101MHz,DMSO-d6)δ192.55,169.80,161.88,145.30,141.43,139.13,132.63,130.27,128.86,127.53,126.89,126.50,119.28,95.80,79.76,73.31,18.44.HR-MS(ESI):Calcd for.C15H11Cl F3N4S[M+H]+：371.0345，found:371.0344.
实施例5(E)-4-(2-(3-氯苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5e)
用3-氯苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率59.8％；1H NMR(400MHz,DMSO-d6)δ12.28(s,1H),8.19(s,1H),7.86(s,1H),7.74(s,1H),7.48(d,J＝4.7Hz,2H),7.34(s,1H),3.99(d,J＝2.5Hz,2H),3.18(t,J＝2.5Hz,1H).13C NMR(101MHz,DMSO-d6)δ169.94,162.12,153.79,144.21,136.05,133.69,130.65,129.68,126.38,125.72,121.93,119.20,96.15,79.87,73.44,18.58.HR-MS(ESI):Calcd for.C15H11Cl F3N4S[M+H]+：371.0345，found:371.0344.
实施例6(E)-4-(2-(4-氯苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5f)
用4-氯苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率60.3％；1H NMR(400MHz,DMSO-d6)δ12.11(s,1H),8.51(s,1H),7.86(d,J＝7.6Hz,1H),7.31–7.25(m,3H),7.20(s,1H),3.99(d,J＝2.5Hz,2H),3.19(t,J＝2.5Hz,1H).13C NMR(101MHz,DMSO-d6)δ169.84,161.69,144.75,136.84,131.74,130.80,129.66,129.43,126.10,121.77,119.19,95.76,79.90,73.39,19.20,18.57.HR-MS(ESI):Calcd for.C15H11Cl F3N4S[M+H]+：371.0345，found:371.0344.
实施例7(E)-4-(2-(3,4-二氟苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5g)
用3,4-二氟苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率33.1％；1H NMR(400MHz,DMSO-d6)δ12.26(s,1H),8.16(s,1H),7.94(d,J＝8.3Hz,1H),7.64–7.57(m,1H),7.51(dd,J＝10.3,8.4Hz,1H),7.36(s,1H),3.98(d,J＝2.6Hz,2H),3.18(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ169.86,161.93,159.82,143.02,132.04,124.39,121.52,119.14,117.99,117.70,116.50,115.40,115.22,96.20,80.14,73.71,18.49.HR-MS(ESI)calcd for C15H10F5N4S[M+H]+:373.0546,found:373.0547.
实施例8(E)-4-(2-(2-甲基亚苄基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5h)
用2-甲基苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率59.0％；1H NMR(400MHz,DMSO-d6)δ12.14(s,1H),8.57(s,1H),7.94(dd,J＝7.7,1.4Hz,1H),7.46–7.39(m,1H),7.25(s,1H),7.10(d,J＝8.2Hz,1H),7.02(t,J＝7.5Hz,1H),3.98(d,J＝2.6Hz,2H),3.87(s,3H),3.18(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ192.55,169.80,161.88,145.30,141.43,139.13,132.63,130.27,128.86,127.53,126.89,126.50,119.28,95.80,79.76,73.31,18.44.HR-MS(ESI)calcdfor C16H15F3N4OS[M+OH]-:367.0840,found:367.0800.
实施例9(E)-4-(2-(4-甲基亚苄基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5i)
用4-甲基苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率48.0％；1H NMR(400MHz,DMSO-d6)δ12.12(s,1H),8.18(s,1H),7.65(d,J＝8.1Hz,2H),7.28(d,J＝6.7Hz,1H),7.25(d,J＝4.0Hz,2H),3.98(d,J＝2.5Hz,2H),3.35(s,3H),3.18(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ169.88,161.94,153.55,145.96,139.96,131.11,129.42,129.28,129.06,127.03,121.96,95.84,79.90,73.43,21.01,18.55.HR-MS(ESI)calcd forC16H15F3N4OS[M+OH]-:367.0840,found:367.0841.
实施例10(E)-4-(2-(2-甲氧基亚苄基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5j)
用2-甲氧基苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率47.3％；1H NMR(400MHz,DMSO-d6)δ12.15(s,1H),8.57(s,1H),7.95(dd,J＝7.7,1.3Hz,1H),7.45–7.39(m,1H),7.25(s,1H),7.11(d,J＝8.2Hz,1H),7.02(t,J＝7.5Hz,1H),3.98(d,J＝2.6Hz,2H),3.86(s,3H),3.18(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ169.88,161.93,157.58,153.54,141.45,131.63,125.65,121.85,120.78,119.22,111.81,95.89,79.91,73.41,55.71,18.55.HR-MS(ESI)calcd forC16H14F3N4OS[M+H]+:367.0840,found:367.0841.
实施例11(E)-4-(2-(3-甲氧基亚苄基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5k)
用3-甲氧基苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率47.5％；1H NMR(400MHz,DMSO-d6)δ12.18(s,1H),8.18(s,1H),7.37(s,1H),7.35(d,J＝2.5Hz,1H),7.30(s,1H),7.27(s,1H),7.01(ddd,J＝7.7,2.5,1.6Hz,1H),3.99(d,J＝2.5Hz,2H),3.85–3.80(m,3H),3.18(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ170.08,161.93,159.53,145.70,135.21,129.90,129.63,121.90,119.57,115.95,111.83,95.95,79.87,73.42,55.14,18.56.HR-MS(ESI)calcd forC16H14F3N4OS[M+H]+:367.0840,found:367.0842.
实施例12(E)-4-(2-(4-甲氧基亚苄基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5l)
用4-甲氧基苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率72.1％；1H NMR(400MHz,DMSO-d6)δ12.07(s,1H),8.16(s,1H),7.71(d,J＝8.8Hz,2H),7.23(s,1H),7.01(d,J＝8.8Hz,2H),3.98(d,J＝2.5Hz,2H),3.18(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ192.55,169.80,161.88,145.30,141.43,139.13,132.63,130.27,128.86,127.53,126.89,126.50,119.28,95.80,79.76,73.31,18.44.HR-MS(ESI)calcd for C16H14F3N4OS[M+H]+:367.0840,found:367.0839.
实施例13(E)-4-(2-(2,3-二甲氧基亚苄基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5m)
用2,3-二甲氧基苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率67.2％；1H NMR(400MHz,DMSO-d6)δ12.15(s,1H),8.52(s,1H),7.54(dd,J＝6.7,2.5Hz,1H),7.24(s,1H),7.18–7.10(m,2H),3.99(t,J＝7.9Hz,2H),3.84(s,3H),3.79(s,3H),3.17(t,J＝2.5Hz,1H).13C NMR(101MHz,DMSO-d6)δ192.55,169.80,161.88,145.30,141.43,139.13,132.63,130.27,128.86,127.53,126.89,126.50,119.28,95.80,79.76,73.31,18.44.HR-MS(ESI)calcd for C17H18F3N4O3S[M+H3O]+:415.1052,found:415.2080.
实施例14(E)-4-(2-(苯并[c]噻吩-1-基亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5n)
用2-噻吩甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率70.2％；1H NMR(400MHz,DMSO-d6)δ12.19(s,1H),8.86(s,1H),8.40(s,1H),7.68(d,J＝5.0Hz,1H),7.49(d,J＝2.9Hz,1H),7.06(s,1H),3.98(d,J＝2.5Hz,2H),3.18(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ170.00,161.64,155.72,140.87,138.50,133.75,130.96,130.83,128.96,128.01,79.89,73.46,18.46.HR-MS(ESI)calcd for C13H10F3N4S 2[M+H]+:343.0299,found:343.0300.
实施例15(E)-2-(丙-2-炔-1-基硫基)-4-(2-(吡啶-2-基亚甲基)肼基)-6-(三氟甲基)嘧啶(5o)
用2-吡啶甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率58.6％；1H NMR(400MHz,DMSO-d6)δ12.37(s,1H),8.61(d,J＝4.7Hz,1H),8.25(s,1H),8.11(d,J＝7.9Hz,1H),7.88(dd,J＝10.9,4.5Hz,1H),7.46–7.39(m,1H),7.35(s,1H),4.00(d,J＝2.5Hz,2H),3.19(t,J＝2.5Hz,1H).13C NMR(101MHz,DMSO-d6)δ170.07,162.17,159.73,152.70,149.47,146.42,146.11,136.82,124.34,120.18,96.18,79.85,73.46,20.18,18.61.HR-MS(ESI)calcd for C14H11F3N5S[M+H]+:338.0687,found:338.0686.
实施例16(E)-2-(丙-2-炔-1-基硫基)-4-(2-(吡啶-3-基亚甲基)肼基)-6-(三氟甲基)嘧啶(5p)
用3-吡啶甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率59.4％；1H NMR(400MHz,DMSO-d6)δ12.34(s,1H),8.92(s,1H),8.61(d,J＝4.6Hz,1H),8.24(d,J＝8.3Hz,2H),7.48(dd,J＝7.8,4.6Hz,1H),7.36(s,1H),3.99(d,J＝2.4Hz,2H),3.19(d,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ192.55,169.80,161.88,145.30,141.43,139.13,132.63,130.27,128.86,127.53,126.89,126.50,119.28,95.80,79.76,73.31,18.44.HR-MS(ESI)calcd for C14H11F3N5S[M+H]+:338.0687,found:338.0685.
实施例17(E)-2-(丙-2-炔-1-基硫基)-4-(2-(吡啶-4-基亚甲基)肼基)-6-(三氟甲基)嘧啶(5q)
用4-吡啶甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率72.1％；1H NMR(400MHz,DMSO-d6)δ12.44(s,1H),8.65(d,J＝5.4Hz,2H),8.19(s,1H),7.74(d,J＝5.9Hz,2H),7.37(s,1H),4.00(d,J＝2.5Hz,2H),3.19(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ192.55,169.80,161.88,145.30,141.43,139.13,132.63,130.27,128.86,127.53,126.89,126.50,119.28,95.80,79.76,73.31,18.44.HR-MS(ESI)calcd for C14H11F3N5S[M+H]+:338.0687,found:338.0688.
实施例18(E)-4-(2-(蒽-9-基亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5s)
用9-蒽甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率58.4％；1H NMR(400MHz,DMSO-d6)δ12.40(s,1H),9.46(s,1H),8.75(s,1H),8.62(d,J＝8.7Hz,2H),8.18(d,J＝8.3Hz,2H),7.71–7.64(m,2H),7.63–7.57(m,2H),7.16(s,1H),4.04(s,2H),3.22(t,J＝2.5Hz,1H).13C NMR(101MHz,DMSO-d6)δ159.72,149.63,146.39,145.01,143.94,130.99,130.88,129.51,129.05,128.99,128.46,127.29,126.94,125.54,124.65,124.42,119.14,101.69,95.64,79.95,73.44,20.18,18.66.HR-MS(ESI)calcd forC23H16F3N4S[M+H]+:437.1048,found:437.1234.
实施例19(E)-4-(2-([1,1'-联苯]-4-基亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶(5w)
用4-苯基苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率72.3％；1H NMR(400MHz,DMSO-d6)δ12.23(s,1H),8.26(s,1H),7.86(d,J＝8.3Hz,2H),7.76(d,J＝8.3Hz,2H),7.72(d,J＝7.5Hz,2H),7.50(t,J＝7.6Hz,3H),7.40(t,J＝7.3Hz,1H),7.30(s,1H),3.99(d,J＝2.4Hz,2H),3.18(t,J＝2.5Hz,1H).13CNMR(101MHz,DMSO-d6)δ192.55,169.80,161.88,145.30,141.43,139.13,132.63,130.27,128.86,127.53,126.89,126.50,119.28,95.80,79.76,73.31,18.44.HR-MS(ESI)calcdfor C23H16F3N4S[M+H]+:437.1048,found:437.1234.
实施例20(E)-3-((2-(2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶-4-基)亚肼基)甲基)苯酚(5t)
用3-羟基苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率47.5％；1H NMR(400MHz,DMSO-d6)δ12.15(s,1H),9.64(s,1H),8.14(s,1H),7.26(t,J＝7.8Hz,1H),7.21(d,J＝7.1Hz,2H),7.14(d,J＝7.6Hz,1H),6.89–6.80(m,1H),3.99(d,J＝2.5Hz,2H),3.18(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ169.97,161.98,157.65,154.04,146.03,135.03,129.90,121.94,119.21,118.65,117.49,112.58,95.76,79.90,73.42,18.57.HR-MS(ESI)calcd for C15H12F3N4OS[M+H]+:353.0684,found:353.0683.
实施例21(E)-4-((2-(2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶-4-基)亚肼基)甲基)苯酚(5u)
用4-羟基苯甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率48.4％；1H NMR(400MHz,DMSO-d6)δ11.34(s,1H),9.96(s,1H),8.12(s,1H),7.60(d,J＝8.6Hz,2H),7.20(s,1H),6.84(d,J＝8.6Hz,2H),3.97(d,J＝2.5Hz,2H),3.17(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ159.74,159.50,151.63,151.29,149.66,146.45,146.24,128.86,124.83,122.06,119.33,115.73,101.70,73.40,20.18,18.51.HR-MS(ESI)calcd for C15H12F3N4OS[M+H]+:353.0684,found:353.0683.
实施例22(E)-1-((2-(2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶-4-基)亚肼基)甲基)-3H-异吲哚(5v)
用3-吲哚甲醛替代3-氟苯甲醛，制备方法同实施例2。
白色固体粉末，收率53.5％；1H NMR(400MHz,DMSO-d6)δ11.69(s,1H),9.94(s,1H),8.44(s,1H),8.29(d,J＝3.1Hz,1H),8.10(d,J＝7.4Hz,2H),7.89(d,J＝2.6Hz,1H),7.52(d,J＝8.0Hz,1H),7.16(s,1H),4.00(t,J＝6.5Hz,2H),3.19(t,J＝2.6Hz,1H).13C NMR(101MHz,DMSO-d6)δ184.91,169.60,161.24,143.65,138.38,137.12,137.02,130.81,124.09,123.41,122.07,120.78,118.14,112.37,111.02,80.02,73.42,18.49.HR-MS(ESI)calcd for C17H13F3N5S[M+H]+:376.0844,found:376.4000.
应用实例
体外抗肿瘤活性测试：以MTT法采用三种细胞系，分别为人乳腺癌细胞(MCF-7)、胃癌细胞(MGC-803)、前列腺癌细胞(PC-3)。
收集对数期细胞，调整细胞悬液浓度，每孔加入100μl，铺板调整待测细胞密度，(边缘孔用PBS填充)。体积百分比5％CO2下37℃孵育24h，至细胞单层铺满孔底(96孔平地板)，加入浓度梯度本发明合成的药物，设9个浓度，每孔200μl，设3个复孔。体积百分比5％CO2下37℃孵育72h，倒置显微镜下观察，每孔加入20μl MTT溶液(5mg/ml，即0.5％MTT)，继续培养4h后终止培养，吸去孔内培养液，每孔加入150μl二甲基亚砜，置摇床上低速振荡10min，使结晶物充分溶解。在酶联免疫检测仪OD490 nm处测量各孔的吸光值。用SPSS软件对实验结果进行统计并计算IC50(μmol/L)值，结果如下表1。
表1体外抗肿瘤活性测试表
Claims (5)
1.含席夫碱结构单元的三氟甲基嘧啶类衍生物，其特征在于，其具有通式Ⅰ所述结构：
通式Ⅰ中：R为苯基、3-氟苯基、4-氟苯基、2-氯苯基、3-氯苯基、4-氯苯基、3,4-二氟苯基、2-甲基苯基、4-甲基苯基、2-噻吩基2-吡啶基、3-吡啶基、4-吡啶基、9-蒽基、4-苯基苯基、4-羟基苯基、3-羟基苯基或3-吲哚基。
2.如权利要求1所述的含席夫碱结构单元的三氟甲基嘧啶类衍生物，其特征在于：选自以下化合物之一：
5a:(E)-4-(2-苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5b:(E)-4-(2-(3-氟苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5c:(E)-4-(2-(4-氟苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5d:(E)-4-(2-(2-氯苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5e:(E)-4-(2-(3-氯苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5f:(E)-4-(2-(4-氯苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5g:(E)-4-(2-(3,4-二氟苯亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5h:(E)-4-(2-(2-甲基亚苄基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5i:(E)-4-(2-(4-甲基亚苄基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5n:(E)-4-(2-(噻吩-1-基亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5o:(E)-2-(丙-2-炔-1-基硫基)-4-(2-(吡啶-2-基亚甲基)肼基)-6-(三氟甲基)嘧啶；
5p:(E)-2-(丙-2-炔-1-基硫基)-4-(2-(吡啶-3-基亚甲基)肼基)-6-(三氟甲基)嘧啶；
5q:(E)-2-(丙-2-炔-1-基硫基)-4-(2-(吡啶-4-基亚甲基)肼基)-6-(三氟甲基)嘧啶；
5s:(E)-4-(2-(蒽-9-基亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5w:(E)-4-(2-([1,1'-联苯]-4-基亚甲基)肼基)-2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶；
5t:(E)-3-((2-(2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶-4-基)亚肼基)甲基)苯酚；
5v:(E)-1-((2-(2-(丙-2-炔-1-基硫代)-6-(三氟甲基)嘧啶-4-基)亚肼基)甲基)-2H-吲哚。
3.制备如权利要求1所述的含席夫碱结构单元的三氟甲基嘧啶类衍生物的方法，其特征在于，通过如下合成步骤实现：
a.将2-巯基-6-(三氟甲基)嘧啶-4-醇和溴代丙炔、氢氧化钾水溶液加入反应器中进行反应，得到化合物2；b.化合物2与三氯氧磷反应，生成化合物3；c.化合物3与水合肼在无水乙醇中反应生成化合物4；d.化合物4与不同的醛类化合物反应得到目标化合物；
所述的醛类化合物为：苯甲醛、3-氟苯甲醛、4-氟苯甲醛、2-氯苯甲醛、3-氯苯甲醛、4-氯苯甲醛、3,4-二氟苯甲醛、2-甲基苯甲醛、4-甲基苯甲醛、2-噻吩甲醛、2-吡啶甲醛、3-吡啶甲醛、4-吡啶甲醛、9-蒽醛、4-苯基苯甲醛、4-羟基苯甲醛、3-羟基苯甲醛或3-吲哚甲醛。
4.如权利要求1-2其中之一所述的含席夫碱结构单元的三氟甲基嘧啶类衍生物在药物制备中的应用，其特征在于，作为活性成分用于制备抗肿瘤药物。
5.如权利要求4所述的含席夫碱结构单元的三氟甲基嘧啶类衍生物在药物制备中的应用，其特征在于，作为活性成分用于制备抗乳腺癌细胞、胃癌细胞或前列腺癌细胞药物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010057671.7A CN111187220B (zh) | 2020-01-19 | 2020-01-19 | 含席夫碱结构单元的三氟甲基嘧啶类衍生物及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010057671.7A CN111187220B (zh) | 2020-01-19 | 2020-01-19 | 含席夫碱结构单元的三氟甲基嘧啶类衍生物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111187220A CN111187220A (zh) | 2020-05-22 |
| CN111187220B true CN111187220B (zh) | 2022-08-02 |
Family
ID=70704161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010057671.7A Expired - Fee Related CN111187220B (zh) | 2020-01-19 | 2020-01-19 | 含席夫碱结构单元的三氟甲基嘧啶类衍生物及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111187220B (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005120046A (ja) * | 2003-10-20 | 2005-05-12 | Sankyo Co Ltd | ピリミジン誘導体を含有する医薬 |
| CN104119280A (zh) * | 2014-06-27 | 2014-10-29 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
| CN106432247A (zh) * | 2016-09-27 | 2017-02-22 | 郑州大学 | 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用 |
| CN109438365A (zh) * | 2018-12-06 | 2019-03-08 | 华南师范大学 | N-(3-((4-三氟甲基)-2-嘧啶基)氨基苯基)-2,6-二氟苯磺酰胺衍生物 |
| WO2020009971A1 (en) * | 2018-07-05 | 2020-01-09 | Mayo Foundation For Medical Education And Research | Pikfyve inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE407678T1 (de) * | 2001-10-17 | 2008-09-15 | Boehringer Ingelheim Pharma | Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung |
| CL2007002231A1 (es) * | 2006-08-02 | 2008-04-11 | Basf Ag | Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico. |
-
2020
- 2020-01-19 CN CN202010057671.7A patent/CN111187220B/zh not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005120046A (ja) * | 2003-10-20 | 2005-05-12 | Sankyo Co Ltd | ピリミジン誘導体を含有する医薬 |
| CN104119280A (zh) * | 2014-06-27 | 2014-10-29 | 郑州大学 | 含氨基类脲与端炔结构单元的嘧啶衍生物、制备方法及应用 |
| CN106432247A (zh) * | 2016-09-27 | 2017-02-22 | 郑州大学 | 含有腙键的嘧啶并三氮唑类化合物、制备方法及其应用 |
| WO2020009971A1 (en) * | 2018-07-05 | 2020-01-09 | Mayo Foundation For Medical Education And Research | Pikfyve inhibitors |
| CN109438365A (zh) * | 2018-12-06 | 2019-03-08 | 华南师范大学 | N-(3-((4-三氟甲基)-2-嘧啶基)氨基苯基)-2,6-二氟苯磺酰胺衍生物 |
Non-Patent Citations (3)
| Title |
|---|
| LPE-1, an orally active pyrimidine derivative, inhibits growth and mobility of human esophageal cancers by targeting LSD1;Bo Wang et al.;《Pharmacological Research》;20170530;第122卷;第66-77页 * |
| 新型嘧啶类耐药逆转剂及其逆转ABCB1介导的MDR的机制研究;王博;《中国优秀博硕士学位论文全文数据库(博士)医药卫生科技辑》;20190715(第07期);E079-29 * |
| 新型腙基取代嘧啶衍生物的合成及抗肿瘤活性评价;张洋 等;《有机化学》;20201231;第40卷;第1731-1736页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111187220A (zh) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106573906A (zh) | 哌啶‑二酮衍生物 | |
| CN104292170B (zh) | 具有抗肿瘤作用的喹唑啉-芳基脲衍生物及其应用 | |
| CN102603743A (zh) | 抗肿瘤的氮杂苯并[f]薁衍生物其制备方法及其用途 | |
| CN107759600A (zh) | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 | |
| CN105985342A (zh) | 作为egfr抑制剂的嘧啶并嘧啶二酮衍生物及其应用 | |
| CN106660970B (zh) | 喹唑啉衍生物 | |
| CN106674242B (zh) | 一种具有抗肿瘤活性的莪术醇衍生物及其制备方法和应用 | |
| WO2020224626A1 (zh) | 用作激酶抑制剂的化合物及其应用 | |
| CN102153508B (zh) | 3,5-(e)-二亚苄基-n-环丙基哌啶-4-酮及其在制备治疗抗肿瘤药物中的应用 | |
| CN111187220B (zh) | 含席夫碱结构单元的三氟甲基嘧啶类衍生物及其制备方法和用途 | |
| CN101691353A (zh) | N-Boc-3,5-(E)-二芳基亚甲基-4-哌啶酮及其在制备治疗抗肿瘤药物中的应用 | |
| CN107739381B (zh) | 莪术醇衍生物及其在制备抗肿瘤药物中的应用 | |
| CN104974132B (zh) | 多取代的吡啶化合物、制备方法、用途及药物组合物 | |
| CN110606843A (zh) | 双吡啶酮腙-2-乙酰基吡嗪的结构、制备和用途 | |
| CN110128343A (zh) | 一种酰肼类化合物 | |
| CN102060848A (zh) | 芳香胺取代的嘧啶衍生物的制备及用途 | |
| CN105017162A (zh) | 4-对丙烯基苯氨基喹唑啉衍生物及其在制备抗肿瘤药物中的应用 | |
| Rajendar et al. | Synthesis and biological evolution of aryl quinolin-benzimidazole-1, 2, 3-triazole as anticancer agents | |
| CN109651341A (zh) | 二吗啉氰基嘧(吡)啶类衍生物及作为抗肿瘤药物应用 | |
| CN109824572B (zh) | 4-羟基二苯甲酮腙-1-甲基-3吲哚甲醛席夫碱的结构、制备和用途 | |
| CN103665046A (zh) | 钌配合物及其制备方法和应用 | |
| WO2021249558A1 (zh) | 作为rsk抑制剂的蝶啶酮衍生物及其应用 | |
| CN110526854A (zh) | 一种ɑ,β-不饱和酮衍生物、制备方法及作为药物的用途 | |
| CN105949117B (zh) | 含查尔酮类似结构的索拉非尼衍生物及其制备方法和应用 | |
| CN114394934B (zh) | 吡唑苯甲酰胺类化合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220802 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |